checkAd

    EQS-News  145  0 Kommentare Gerresheimer partners with RxCap to offer connected adherence solutions

    Für Sie zusammengefasst
    • Gerresheimer partners with RxCap for adherence solutions in the U.S.
    • Centor gets exclusive distribution rights for pharmacies in the U.S.
    • Digital therapy support improves health outcomes and patient adherence.

    EQS-News: Gerresheimer AG / Key word(s): Contract/Investment
    Gerresheimer partners with RxCap to offer connected adherence solutions

    29.04.2024 / 13:00 CET/CEST
    The issuer is solely responsible for the content of this announcement.


    Gerresheimer partners with RxCap to offer connected adherence solutions 

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Gerresheimer AG!
    Long
    93,43€
    Basispreis
    0,75
    Ask
    × 13,23
    Hebel
    Short
    107,24€
    Basispreis
    0,76
    Ask
    × 13,06
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    • Gerresheimer subsidiary Centor receives exclusive distribution rights for pharmacies in the U.S.
    • Adherence solutions enables pharmacies to offer remote therapeutic monitoring
    • Digital therapy support leads to improved health outcomes

    Düsseldorf/Berlin, Ohio, USA, April 29, 2024 – Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, has entered into a partnership with the US digital health company RxCap and acquired a minority stake. Under the terms of the agreement, Gerresheimer's subsidiary Centor will receive the exclusive distribution rights for pharmacies in the U.S. for adherence solutions by RxCap, consisting of connected prescription vial closure devices and complementary cloud-based software. Centor is the U.S. market leader in prescription vials and is uniquely positioned to enable smart adherence solutions through existing pharmacy workflows.

     "The adherence solutions from RxCap is an ideal complement to the Centor prescription vials", says Tony Haba, Senior Vice President North America at Gerresheimer. "Solutions for digital therapy support are a future growth market for Gerresheimer. That is why we are increasingly offering our customers innovative solutions consisting of connected primary packaging and digital monitoring platforms. The partnership with RxCap is an excellent example of this."

    “Our mission is to help people stay adherent to their medications and improve their care outcomes,” says Sreeram Ramakrishnan, CEO of RxCap. “By partnering with Centor – an innovative market leader with strong relations with pharmacies, we will be able to grow the number of patients we serve. Moreover, Gerresheimer’s expertise in primary packaging and access to pharmacy leaders will enable us to develop additional adherence solutions that amplify our impact.”

    Seite 1 von 4


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News Gerresheimer partners with RxCap to offer connected adherence solutions EQS-News: Gerresheimer AG / Key word(s): Contract/Investment Gerresheimer partners with RxCap to offer connected adherence solutions 29.04.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. Gerresheimer …

    Schreibe Deinen Kommentar

    Disclaimer